The immune system and response to HER2-targeted treatment in breast cancer.

Abstract

The monoclonal antibody trastuzumab targets the growth factor receptor HER2 and has profoundly improved the course of disease and survival of women with HER2-overexpressing breast cancer. Because trastuzumab targets aberrant expression of HER2 in tumours addicted to HER2 activation, its clinical activity is credited largely to inhibition of intracellular… (More)
DOI: 10.1016/S1470-2045(13)70477-7

Topics

Cite this paper

@article{Bianchini2014TheIS, title={The immune system and response to HER2-targeted treatment in breast cancer.}, author={Giampaolo Bianchini and Luca Gianni}, journal={The Lancet. Oncology}, year={2014}, volume={15 2}, pages={e58-68} }